Market Cap 38.79M
Revenue (ttm) 30,000.00
Net Income (ttm) -14.29M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -47,633.33%
Debt to Equity Ratio 0.00
Volume 48,000
Avg Vol 193,720
Day's Range N/A - N/A
Shares Out 50.05M
Stochastic %K 27%
Beta 0.56
Analysts Strong Sell
Price Target $3.25

Company Profile

Talphera, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings. The company's lead product candidate is Niyad, a lyophilized formulation of nafamostat, which is under an investigational device exemption as an anticoagulant for the extracorporeal circuit. It is also developing LTX-608, a nafamostat formulation for direct IV infusion as an investigational product for various indications, such as antiviral,...

Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Phone: 650 216 3500
Address:
1850 Gateway Drive, Suite 175, San Mateo, United States
grutpeter
grutpeter Apr. 25 at 6:44 PM
$TLPH what's the plan to get this above a dollar or are we headed for a reverse split.
0 · Reply
Brunoez
Brunoez Apr. 16 at 3:15 PM
$TLPH Very low volume, but the price is holding up a little better the past few days. Today's low of .82 takes us all the way back to early March when the highs were still in the .90-1.00 range. Still a long way to go, of course.
0 · Reply
Yoda896
Yoda896 Apr. 16 at 9:37 AM
$TLPH How could it be 30, give or take, when they confirmed "way past 38," 3 weeks ago? Do yourself a favor and read the transcript of the March 23rd CC.
2 · Reply
aj_
aj_ Apr. 15 at 2:48 PM
$TLPH this is standard of care in Japan and South Korea, they have tested 30 people give or take. When the Fark are they going to get this going? Hmm
0 · Reply
Yoda896
Yoda896 Apr. 15 at 9:10 AM
$TLPH This is not TLPH and is not the Niyad test. It's someone else in China testing Nafamostat, as many others around the World have been doing, with very good results. More NM tests are good for us because they give the FDA more data about the main ingredient NM in Niyad. That's the main reason the FDA agreed to reduce Niyad phase 3 from 166 to 70.
0 · Reply
aj_
aj_ Apr. 14 at 9:57 PM
$TLPH now they’re looking for 1162 patients. What happened to the 180? Lol, Vince is a champ.
0 · Reply
Crandaddy01
Crandaddy01 Apr. 14 at 5:33 AM
0 · Reply
watchaddict
watchaddict Apr. 10 at 2:18 PM
$TLPH adding
1 · Reply
nazzangr
nazzangr Apr. 10 at 1:39 AM
$TLPH idk if this result was alrdy posted but this would be a very interesting clinical trial https://clinicaltrials.gov/study/NCT07518303?aggFilters=phase:0%201%202%203%204,status:not%20rec%20act%20enr,studyType:int&primComp=2020-01-01_&lastUpdPost=2024-11-08_
1 · Reply
aj_
aj_ Apr. 8 at 3:51 PM
$TLPH data, let’s go. Data, progress. Let’s go Vince gdannut.
0 · Reply
Latest News on TLPH
CorMedix Announces Strategic Minority Investment in Talphera

Sep 8, 2025, 8:30 AM EDT - 8 months ago

CorMedix Announces Strategic Minority Investment in Talphera

CRMD


Talphera to Participate at A.G.P. Virtual Healthcare Conference

May 16, 2024, 5:45 PM EDT - 2 years ago

Talphera to Participate at A.G.P. Virtual Healthcare Conference


grutpeter
grutpeter Apr. 25 at 6:44 PM
$TLPH what's the plan to get this above a dollar or are we headed for a reverse split.
0 · Reply
Brunoez
Brunoez Apr. 16 at 3:15 PM
$TLPH Very low volume, but the price is holding up a little better the past few days. Today's low of .82 takes us all the way back to early March when the highs were still in the .90-1.00 range. Still a long way to go, of course.
0 · Reply
Yoda896
Yoda896 Apr. 16 at 9:37 AM
$TLPH How could it be 30, give or take, when they confirmed "way past 38," 3 weeks ago? Do yourself a favor and read the transcript of the March 23rd CC.
2 · Reply
aj_
aj_ Apr. 15 at 2:48 PM
$TLPH this is standard of care in Japan and South Korea, they have tested 30 people give or take. When the Fark are they going to get this going? Hmm
0 · Reply
Yoda896
Yoda896 Apr. 15 at 9:10 AM
$TLPH This is not TLPH and is not the Niyad test. It's someone else in China testing Nafamostat, as many others around the World have been doing, with very good results. More NM tests are good for us because they give the FDA more data about the main ingredient NM in Niyad. That's the main reason the FDA agreed to reduce Niyad phase 3 from 166 to 70.
0 · Reply
aj_
aj_ Apr. 14 at 9:57 PM
$TLPH now they’re looking for 1162 patients. What happened to the 180? Lol, Vince is a champ.
0 · Reply
Crandaddy01
Crandaddy01 Apr. 14 at 5:33 AM
0 · Reply
watchaddict
watchaddict Apr. 10 at 2:18 PM
$TLPH adding
1 · Reply
nazzangr
nazzangr Apr. 10 at 1:39 AM
$TLPH idk if this result was alrdy posted but this would be a very interesting clinical trial https://clinicaltrials.gov/study/NCT07518303?aggFilters=phase:0%201%202%203%204,status:not%20rec%20act%20enr,studyType:int&primComp=2020-01-01_&lastUpdPost=2024-11-08_
1 · Reply
aj_
aj_ Apr. 8 at 3:51 PM
$TLPH data, let’s go. Data, progress. Let’s go Vince gdannut.
0 · Reply
Crandaddy01
Crandaddy01 Apr. 6 at 7:49 PM
0 · Reply
firedupinvestors
firedupinvestors Apr. 6 at 6:44 PM
$TLPH da ship is sinking.
1 · Reply
Burning_Cash
Burning_Cash Apr. 6 at 12:25 PM
$TLPH Loving my 1.38 avg here 😆
3 · Reply
Noname2022
Noname2022 Apr. 2 at 5:47 PM
$CRMD $TLPH $FMS Niyad! Can’t help but thinking Cormedix relationships with FMS along with FMS interest in the CRRT space have got to be positives…
0 · Reply
firedupinvestors
firedupinvestors Mar. 31 at 11:18 AM
0 · Reply
Yoda896
Yoda896 Mar. 29 at 11:45 PM
$TLPH Nafamostat may be expensive/unavailable outside Asia now because there is no demand for it right now. But, once Niyad is approved, it will be manufactured and made available at a lower cost than Citrate. Shakil Aslam - 2026/03/23 CC - 0:54:47: "Nafamostat is not gonna be more expensive than citrate."
1 · Reply
nazzangr
nazzangr Mar. 29 at 8:14 PM
$TLPH looks like this is from the conference held this weekends. Looks at the pros and cons lol cons basically only have “expensive” https://kdigo.org/wp-content/uploads/2026/03/KDIGO-2026-AKI-AKD-Guideline-Public-Review-Draft-March-2026.pdf
0 · Reply
CEOBuysDisclosures
CEOBuysDisclosures Mar. 26 at 2:00 AM
$TLPH CEO purchased 213,310 shares at $0.59 for a total of $125,000. Angotti Vincent J. now owns 800,705 shares. https://ceo-buys.com
0 · Reply
nazzangr
nazzangr Mar. 25 at 12:36 PM
$TLPH things are moving lets go
0 · Reply
iLiealot
iLiealot Mar. 25 at 10:49 AM
$TLPH Another call? nice
1 · Reply
Yoda896
Yoda896 Mar. 24 at 9:07 PM
$TLPH Vincent Angotti - March 23, 2026 CC (Location 0:02:28) "As of December 31st, we had cash and investments of $20.4 million, which, along with the remaining tranches, if closed, should provide runway through a potential FDA approval of Niyad next year." Notice he said "if closed" Since they were not closed yet, and as usual, the deal would be for the institutional investors to commit to spend $4.1 million (or more?) at the closing price of a certain day. So, if the day in question is today, as a think it must be, the buyers would try to close the stock at a low price. This way they get more shares for $4.1 million. If I'm right, the stock should start going up tomorrow, and go over $1 very quickly. You said you wanted a dumbass answer. So, there you go ;)
1 · Reply
Crandaddy01
Crandaddy01 Mar. 24 at 8:37 PM
0 · Reply